BeiGene (HKEX: 06160) has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration.
Founded in Beijing 15 years ago, BeiGene has grown into a significant player in oncology, supported by its robust pipeline of treatments for hematologic and solid tumors. The change, pending shareholder approval, will also result in a new Nasdaq ticker, "ONC."
Losing the "Bei,” which calls to mind the firm's Chinese origin, could also help present a more global image, amid an increasingly fractious Sino-American relationship exemplified by the BIOSECURE act.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze